Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769–86.

Article  PubMed  Google Scholar 

Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.

Article  PubMed  PubMed Central  Google Scholar 

Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958–68.

Article  CAS  PubMed  Google Scholar 

Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004;25(1):37–45.

Article  PubMed  Google Scholar 

Ng N, Padilla ML, Camus P. Drug-induced interstitial lung diseases. Immunol Allergy Clin North Am. 2023;43(2):341–57.

Article  PubMed  Google Scholar 

Roden AC, Camus P. Iatrogenic pulmonary lesions. Semin Diagn Pathol. 2018;35(4):260–71.

Article  PubMed  Google Scholar 

Ratwani A, Gupta B, Stephenson BW, Mani H, Brown AW. The spectrum of drug-induced interstitial lung disease. Curr Pulmonol Rep. 2019;8:139–50.

Article  Google Scholar 

Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J. 2022;60(4):2102776.

Article  CAS  PubMed  Google Scholar 

Yong WP, Teo FS, Teo LL, Ng MC, Tan TJ, Low SY, et al. Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opin Drug Metab Toxicol. 2022;18(12):805–15.

Article  PubMed  Google Scholar 

Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004;71(4):301–26.

Article  PubMed  Google Scholar 

Drent M, Jessurun NT, Wijnen PA, Bekers O, Bast A. Drug-induced comorbidities in patients with sarcoidosis. Curr Opin Pulm Med. 2022;28(5):468–77.

Article  PubMed  PubMed Central  Google Scholar 

Jessurun NT, Drent M, van Puijenbroek EP, Bekers O, Wijnen PA, Bast A. Drug-induced interstitial lung disease: role of pharmacogenetics in predicting cytotoxic mechanisms and risks of side effects. Curr Opin Pulm Med. 2019;25(5):468–77.

Article  CAS  PubMed  Google Scholar 

Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case–control study in the Netherlands. Drug Saf. 2008;31(12):1125–34.

Article  PubMed  Google Scholar 

Bast A, Drent M. Altered pharmacology and toxicology during ageing: implications for lung disease. Curr Opin Pulm Med. 2022;28(4):314–20.

Article  PubMed  Google Scholar 

Drent M, Wijnen P, Bast A. Pharmacogenetic variants and vitamin K deficiency: a risk factor or trigger for fibrosing interstitial pneumonias? Curr Opin Pulm Med. 2018;24(3):287–95.

Article  CAS  PubMed  Google Scholar 

McInnes G, Lavertu A, Sangkuhl K, Klein TE, Whirl-Carrillo M, Altman RB. Pharmacogenetics at scale: an analysis of the UK Biobank. Clin Pharmacol Ther. 2021;109(6):1528–37.

Article  PubMed  Google Scholar 

Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–56.

Article  CAS  PubMed  Google Scholar 

Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab. 2006;7(8):939–48.

Article  CAS  PubMed  Google Scholar 

Wijnen PA, Bekers O, Drent M. Relationship between drug-induced interstitial lung diseases and cytochrome P450 polymorphisms. Curr Opin Pulm Med. 2010;16(5):496–502.

Article  CAS  PubMed  Google Scholar 

Schwaiblmair M, Behr W, Foerg W, Berghaus T. Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. Expert Opin Drug Metab Toxicol. 2011;7(12):1547–60.

Article  CAS  PubMed  Google Scholar 

Drent M, Singh S, Gorgels AP, Hansell DM, Bekers O, Nicholson AG, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med. 2003;167(7):958–61.

Article  PubMed  Google Scholar 

Drent M, Wijnen P, Bast A. Interstitial lung damage due to cocaine abuse: pathogenesis, pharmacogenomics and therapy. Curr Med Chem. 2012;19(33):5607–11.

Article  CAS  PubMed  Google Scholar 

Jessurun NT, Drent M, Wijnen PA, Harmsze AM, van Puijenbroek EP, Bekers O, et al. Role of drug-gene interactions and pharmacogenetics in simvastatin-associated pulmonary toxicity. Drug Saf. 2021;44(11):1179–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jessurun NT, Wijnen PA, Bast A, van Puijenbroek EP, Bekers O, Drent M. Tamsulosin associated with interstitial lung damage in CYP2D6 variant alleles carriers. Int J Mol Sci. 2020;21(8):2770.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wijnen P, Drent M, Bekers O, Verschakelen J, Bast A. VKORC1 and CYP2C9 polymorphisms: a case report in a Dutch family with pulmonary fibrosis. Int J Mol Sci. 2019;20(5):1160.

Article  CAS  PubMed  PubMed Central  Google Scholar 

KNMP. Algemene achtergrondtekst Farmacogenetica: CYP2D6. 2021. Available from: https://kennisbank.knmp.nl/files/farmacogenetica/achtergrondteksten/cyp2D6.pdf. Accessed 28 Mar 2023.

KNMP. Algemene achtergrondtekst Farmacogenetica: CYP2C19. 2021. Available from: https://kennisbank.knmp.nl/files/farmacogenetica/achtergrondteksten/cyp2C19.pdf. Accessed 28 Mar 2023.

KNMP. Algemene achtergrondtekst Farmacogenetica: CYP2C9. 2022. Available from: https://kennisbank.knmp.nl/files/farmacogenetica/achtergrondteksten/cyp2C9.pdf. Accessed 28 Mar 2023.

Pneumotox. 2023. Available from: http://www.pneumotox.com. Accessed 25 May 2023.

Medicines Evaluation Board. Medicines Information Bank. Summary of product characteristics assessed medicines. Available from: http://www.cbg-meb.nl. Accessed 29 Apr 2023.

Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, et al. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021;23(12):2335–41.

Article  PubMed  PubMed Central  Google Scholar 

Rollinson V, Turner R, Pirmohamed M. Pharmacogenomics for primary care: an overview. Genes (Basel). 2020;11(11):1337.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vos CF, Ter Hark SE, Schellekens AFA, Spijker J, van der Meij A, Grotenhuis AJ, et al. Effectiveness of genotype-specific tricyclic antidepressant dosing in patients with major depressive disorder: a randomized clinical trial. JAMA Netw Open. 2023;6(5): e2312443.

Article  PubMed  PubMed Central  Google Scholar 

Matey ET, Ragan AK, Oyen LJ, Vitek CR, Aoudia SL, Ragab AK, et al. Nine-gene pharmacogenomics profile service: the Mayo Clinic experience. Pharmacogenomics J. 2022;22(1):69–74.

Article  CAS  PubMed  Google Scholar 

Bates DW, Levine DM, Salmasian H, Syrowatka A, Shahian DM, Lipsitz S, et al. The safety of inpatient health care. N Engl J Med. 2023;388(2):142–53.

Article  PubMed  Google Scholar 

Barnes PJ, Anderson GP, Fageras M, Belvisi MG. Chronic lung diseases: prospects for regeneration and repair. Eur Respir Rev. 2021;30(159):14.

Article  Google Scholar 

Peterson PE, Nicholson WT, Moyer AM, Arendt CJ, Smischney NJ, Seelhammer TG, et al. Description of pharmacogenomic testing among patients admitted to the intensive care unit after cardiovascular surgery. J Intensive Care Med. 2021;36(11):1281–5.

Article  PubMed  Google Scholar 

Wijnen PA, Verschakelen JA, Bast A, Bekers O, Drent M. Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger? Lung. 2013;191(1):53–9.

Article  PubMed  Google Scholar 

Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, et al. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47(6):1776–84.

Article  CAS  PubMed  Google Scholar 

Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng H, Feng D, Li X, Gao L, Tang S, Liu W, et al. Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis. Biochim Biophys Acta Mol Basis Dis. 2021;1867(12): 166204.

Article  CAS  PubMed